Definition of the upper reference limit of glycated albumin in blood donors from Italy

Bellia, Chiara; Zaninotto, Martina; Cosma, Chiara; Agnello, Luisa; Sasso, Bruna Lo; Bivona, Giulia; Plebani, Mario; Ciaccio, Marcello

doi:10.1515/cclm-2017-0179

Cited by 35 publications

(19 citation statements)

References 19 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to the reference limits of GA [33], which have been very recently documented also in Caucasians [34, 35] (upper reference limit: 14.5% (95% CI: 14.3–14.7) [34]; range: 9.0% (90% CI: 8.7–9.5) to 16.0% (90% CI: 15.6–16.4) [35]), in non-DM CKD-G5D patients, GA (95% CI: 12.52–13.66) was within the ranges of normality (Table 1 and Figure 1()). Differently, in the DM CKD-G5D group, it reached pathological levels and it was statistically significantly higher than in the non-DM CKD-G5D patients ( p < 0.001) (Table 1 and Figure 1()).…”

Section: Resultsmentioning

confidence: 99%

Increased Levels of sRAGE in Diabetic CKD-G5D Patients: A Potential Protective Mechanism against AGE-Related Upregulation of Fibroblast Growth Factor 23 and Inflammation

Dozio

Corradi

Vianello

et al. 2017

Mediators of Inflammation

View full text Add to dashboard Cite

Advanced glycation end products (AGEs) may induce cardiac remodeling in kidney disease by promoting fibroblast growth factor 23 (FGF-23) expression. Since AGEs are increased in diabetes mellitus (DM), our first aim was to evaluate the existence of any potential association between AGEs, FGF-23, inflammation, and increased cardiovascular risk in DM patients on dialysis (CKD-G5D). Secondarily, we explored the potential role of the soluble receptor for AGEs (sRAGE) as a marker of heart failure. Levels of glycated albumin (GA), sRAGE, c-terminal FGF-23 (cFGF-23), brain natriuretic peptide (BNP), and inflammatory mediators were compared between DM and non-DM CKD-G5D patients. The levels of sRAGE, cFGF-23, BNP, and proinflammatory markers were over the ranges of normality in both DM and non-DM groups. Only GA and sRAGE levels were increased in DM compared to non-DM patients. Plasma levels of sRAGE and CRP were the only independent predictors of BNP concentration. In conclusion, in DM CKD-G5D patients, sRAGE appeared to be a marker of cardiac remodeling. Indeed, its increase could be a potential protective mechanism against the increased risk of cardiovascular complications related to AGEs and inflammation. The causal relationship between sRAGE and cardiovascular risk in these patients needs to be further confirmed by mechanistic studies.

show abstract

Section: Resultsmentioning

confidence: 99%

Increased Levels of sRAGE in Diabetic CKD-G5D Patients: A Potential Protective Mechanism against AGE-Related Upregulation of Fibroblast Growth Factor 23 and Inflammation

Dozio

Corradi

Vianello

et al. 2017

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…First, the selection of a “really” healthy population is essential for accurately defining reference values of any clinically usable biomarker. However, how to precisely define a “healthy” reference population is currently debatable ( 23 , 24 ). Apple and Collinson recently defined what should constitute a healthy reference population, by emphasizing that the selection should be based on history of medications and the presence of a known underlying disease, as well as by identifying the possible presence of occult organ dysfunction by measuring some surrogate biomarkers ( 25 ).…”

Section: Discussionmentioning

confidence: 99%

Establishing the upper reference limit of Galectin-3 in healthy blood donors

Agnello¹,

Bellia²,

Sasso³

et al. 2017

Biochemia Medica

Self Cite

View full text Add to dashboard Cite

IntroductionGalectin-3 (Gal-3) is an independent predictor of poor outcomes and mortality in patients with heart failure (HF). Thus, it has been proposed as a reliable prognostic biomarker for HF. The definition of reference intervals is mandatory for interpreting the findings of experimental studies and encouraging the routine use of biomarkers in clinical practice. To date, no study assessed the reference intervals of Gal-3 and identified the biological variables that affect its concentration in a well-defined healthy population. The aim of this study was to determine the upper reference limit (URL) of Gal-3 in a highly reliable population of healthy subjects.Materials and methodsWe recruited 714 blood donors. After measuring surrogate biomarkers to identify underlying diseases, 8 subjects were excluded. A final population of 706 individuals (385 men (54.5%); median age 39 (18-65) years) was included. The URL was calculated using the non-parametric percentile approach.ResultsThe 97.5th percentile URL of plasma Gal-3 in our study population (90% CI) was 26.1 (23.3–31.5) ng/mL. After stratifying subjects according to age, the URL of Gal-3 was found to be considerably higher in older (> 45 years) than in younger subjects (31.5 (26.2–51.4) vs 21.8 (21–26.1) ng/mL, respectively). No sex-related differences were found in Gal-3 plasma concentration.ConclusionsWe established the URL of Gal-3 in a highly selected healthy population. Our findings indicate that age is an important determinant of Gal-3 plasma concentration, so that multiple diagnostic cut-offs should be preferably used according to the different age classes.

show abstract

“…GA >15.2% [24] and >15.5% [25] were the cut-offs proposed for DM screening. Normal GA levels were recently recorded also in Caucasian subjects and 15.5% was identified as the healthy upper limit for GA in over 1,300 healthy blood donors aged 18-65 years [26,27].…”

Section: Glycated Albumin In Comparison To Other Glycemic Indicesmentioning

confidence: 95%

Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D)

Dozio

Corradi

Proglio

et al. 2018

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

In chronic kidney disease patients on dialysis (CKD-G5D) accurate assessment of glycemic control is vital to improve their outcome and survival. The best glycemic marker for glucose control in these patients is still debated because several clinical and pharmacological factors may affect the ability of the available biomarkers to reflect the patient's glycemic status properly. This review discusses the role of glycated albumin (GA) both as a biomarker for glucose control and as a prognostic factor in CKD-G5D; it also looks at the pros and cons of GA in comparison to the other markers and its usefulness in hemodialysis and peritoneal dialysis.

show abstract

Definition of the upper reference limit of glycated albumin in blood donors from Italy

Cited by 35 publications

References 19 publications

Increased Levels of sRAGE in Diabetic CKD-G5D Patients: A Potential Protective Mechanism against AGE-Related Upregulation of Fibroblast Growth Factor 23 and Inflammation

Increased Levels of sRAGE in Diabetic CKD-G5D Patients: A Potential Protective Mechanism against AGE-Related Upregulation of Fibroblast Growth Factor 23 and Inflammation

Establishing the upper reference limit of Galectin-3 in healthy blood donors

Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D)

Contact Info

Product

Resources

About